Kazunori Fujitaka Selected Research

Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)

2/2024	Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study.
10/2023	A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR mutations.
2/2023	Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial-Mesenchymal Transition.
12/2022	Pre-Existing Interstitial Lung Abnormalities Are Independent Risk Factors for Interstitial Lung Disease during Durvalumab Treatment after Chemoradiotherapy in Patients with Locally Advanced Non-Small-Cell Lung Cancer.
11/2022	Predictive role of circulatory levels of high-mobility group box 1 for radiation pneumonitis in patients with non-small cell lung cancer treated with definitive thoracic radiotherapy.
8/2022	First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study.
6/2022	Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer.
6/2022	Multi-institutional feasibility study of intensity-modulated radiotherapy with chemotherapy for locally advanced non-small cell lung cancer.
1/2022	Phase 2 study of first-line pembrolizumab monotherapy in elderly patients with non-small-cell lung cancer expressing high PD-L1.
1/2022	First-line osimertinib treatment in a patient with lung adenocarcinoma with coexisting epidermal growth factor receptor G719S and de novo T790M mutations.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kazunori Fujitaka Research Topics

Disease

33	Neoplasms (Cancer) 01/2024 - 03/2011
32	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2024 - 06/2004
26	Lung Neoplasms (Lung Cancer) 01/2024 - 03/2011
19	Interstitial Lung Diseases (Interstitial Lung Disease) 11/2023 - 12/2005
12	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2024 - 01/2009
10	Fibrosis (Cirrhosis) 01/2024 - 01/2017
9	Idiopathic Pulmonary Fibrosis 05/2024 - 04/2010
9	Lung Injury 05/2024 - 04/2009
8	Asthma (Bronchial Asthma) 10/2023 - 01/2009
8	Adenocarcinoma of Lung 01/2022 - 06/2011
6	Neoplasm Metastasis (Metastasis) 09/2020 - 03/2011
5	Adenocarcinoma 01/2023 - 03/2011
5	Disease Progression 07/2022 - 12/2018
5	Bronchiectasis 02/2021 - 01/2018
4	Pneumonia (Pneumonitis) 10/2022 - 07/2011
4	Venous Thromboembolism 01/2022 - 03/2019
3	Acute Lung Injury 05/2024 - 01/2020
3	Radiation Pneumonitis 11/2022 - 10/2021
3	Hemorrhage 01/2022 - 08/2018
3	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 11/2021 - 10/2017
3	Emphysema 04/2021 - 01/2016
3	Inflammation (Inflammations) 01/2021 - 11/2017
3	Lewis Lung Carcinoma 09/2018 - 11/2013
2	Carcinogenesis 11/2022 - 10/2020
2	Respiratory Insufficiency (Respiratory Failure) 02/2022 - 01/2017
2	Dyspnea (Shortness of Breath) 02/2021 - 12/2005
2	Sarcoidosis (Schaumann Disease) 01/2021 - 05/2012
2	Carcinoma (Carcinomatosis) 01/2021 - 06/2011
2	Intracranial Embolism 01/2020 - 03/2019
2	Chronic Obstructive Pulmonary Disease (COPD) 01/2020 - 01/2015
2	Malignant Mesothelioma 01/2018 - 01/2016
2	Lymphangioleiomyomatosis (Lymphangiomyomatosis) 12/2017 - 01/2002
2	Fever (Fevers) 12/2005 - 05/2005
2	Neutropenia 05/2005 - 06/2004
1	Thromboembolism 01/2024
1	Rhinosinusitis 10/2023

Drug/Important Bio-Agent (IBA)

12	ErbB Receptors (EGF Receptor)IBA 02/2024 - 06/2008
11	Bleomycin (Blenoxane)FDA LinkGeneric 05/2024 - 01/2009
10	Biomarkers (Surrogate Marker)IBA 05/2024 - 07/2011
8	Plasminogen Activators (Plasminogen Activator)IBA 02/2023 - 04/2010
8	Plasminogen Activator Inhibitor 1IBA 02/2023 - 04/2010
8	LigandsIBA 07/2022 - 01/2016
6	Immune Checkpoint InhibitorsIBA 02/2024 - 09/2019
6	CytokinesIBA 11/2023 - 01/2009
6	Proteins (Proteins, Gene)FDA Link 01/2023 - 12/2015
6	Tyrosine Kinase InhibitorsIBA 08/2022 - 06/2008
5	HMGB1 Protein (HMG1)IBA 01/2023 - 01/2020
5	Cisplatin (Platino)FDA LinkGeneric 02/2021 - 05/2005
5	Small Interfering RNA (siRNA)IBA 01/2021 - 04/2010
4	AnticoagulantsIBA 01/2024 - 03/2019
4	Bevacizumab (Avastin)FDA Link 10/2023 - 09/2018
4	pembrolizumabIBA 01/2022 - 03/2019
4	Carboplatin (JM8)FDA LinkGeneric 11/2021 - 06/2004
4	AntibodiesIBA 11/2019 - 12/2005
3	osimertinibIBA 02/2023 - 01/2022
3	Messenger RNA (mRNA)IBA 01/2023 - 01/2021
3	Prednisolone (Predate)FDA LinkGeneric 12/2022 - 01/2018
3	SteroidsIBA 12/2022 - 12/2005
3	edoxabanIBA 01/2022 - 03/2019
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2021 - 06/2011
3	Gefitinib (Iressa)FDA Link 10/2021 - 06/2011
3	AntigensIBA 04/2021 - 12/2005
3	Interleukin-6 (Interleukin 6)IBA 01/2021 - 04/2009
3	suplatast tosilateIBA 01/2019 - 01/2009
3	SK-216IBA 01/2016 - 11/2013
3	Paclitaxel (Taxol)FDA LinkGeneric 10/2011 - 06/2004
2	Hydroxyproline (4 Hydroxyproline)IBA 01/2024 - 10/2018
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 10/2023 - 01/2021
2	AfatinibIBA 10/2023 - 01/2019
2	Adrenal Cortex Hormones (Corticosteroids)IBA 09/2023 - 01/2022
2	Prothrombin (Factor II)IBA 01/2023 - 01/2022
2	Immunoglobulin G (IgG)IBA 12/2022 - 04/2022
2	EnzymesIBA 02/2021 - 01/2012
2	NivolumabIBA 02/2021 - 01/2018
2	PlatinumIBA 01/2021 - 01/2019
2	Amino Acyl-tRNA Synthetases (Aminoacyl-tRNA Synthetase)IBA 01/2019 - 12/2018
2	Mucin-1 (CA 15-3 Antigen)IBA 01/2019 - 12/2017
2	ChemokinesIBA 01/2019 - 01/2017
2	Pemetrexed (MTA)FDA Link 12/2018 - 09/2018
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2018 - 11/2013
2	PowdersIBA 09/2018 - 12/2015
2	Docetaxel (Taxotere)FDA Link 09/2018 - 01/2011
2	CD13 Antigens (Alanine Aminopeptidase)IBA 01/2018 - 07/2015
2	Receptor for Advanced Glycation End ProductsIBA 11/2017 - 01/2017
1	Lipocalin-2IBA 05/2024
1	Glycoproteins (Glycoprotein)IBA 05/2024
1	paquinimodIBA 01/2024
1	Hypoxia-Inducible Factor 1IBA 11/2023
1	RNA (Ribonucleic Acid)IBA 11/2023
1	Ascorbic Acid (Vitamin C)FDA LinkGeneric 11/2023

Therapy/Procedure

19	Drug Therapy (Chemotherapy) 07/2022 - 01/2011
11	Therapeutics 01/2024 - 06/2011
7	Radiotherapy 11/2022 - 06/2017
5	Chemoradiotherapy 12/2022 - 10/2017
5	Traction 02/2021 - 01/2018
2	Oral Administration 10/2022 - 06/2017
2	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 06/2022 - 12/2021
2	Nebulizers and Vaporizers (Inhaler) 01/2022 - 09/2018
2	Catheters 01/2020 - 01/2018
1	Cell Transplantation 11/2023